XBiotech announces plans to price initial public offering of stock

Bookrunner WR Hambrecht assists with sale; deal funds clinical trials

By Devika Patel

Knoxville, Tenn., Feb. 2 – XBiotech, Inc. will price its initial public sale of common stock with a 30-day greenshoe, according to a Form S-1 filed Monday with the Securities and Exchange Commission.

WR Hambrecht + Co. is the bookrunning manager.

Proceeds will be used for clinical trials, plant and equipment infrastructure, clinical studies, working capital and general corporate purposes.

The biopharmaceutical company is based in Austin, Texas. It intends to list its common stock on the Nasdaq under the symbol “XBIT.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.